Abstract
Background: To explore the diagnostic value of DNA methylation in early-stage lung cancer using tissue and plasma. Methods: A tissue cohort (n=100) and a plasma cohort (n=146) of patients diagnosed with lung cancer and benign diseases were enrolled and randomly divided into training and validation groups. Methylation profiles were compared to select lung cancer-specific methylation markers. Diagnostic prediction models were constructed using these markers. Their efficacies were estimated by sensitivity, specificity, and AUC. Findings: Diagnostic models were developed to differentiate lung cancer from benignity. In the tissue cohort, 276 markers were significantly differentially methylated in lung cancer (FDR<0.05). A diagnostic prediction model of 6 markers from these achieved outstanding performances in both training cohort (Sensitivity 90%, Specificity 97%, AUC 0.988) and validation cohort (Sensitivity 92%, Specificity 94%, AUC 0.977). These markers were not significantly differentially methylated in the plasma samples. Thus, another 15 markers were selected independently in the plasma samples, yielding a sensitivity of 98% and a specificity of 100% (AUC 0.998) in the training cohort and a sensitivity of 81% and a specificity of 59% (AUC 0.797) in the validation cohort. Analysis based on the methylation haplotype was also conducted, identifying 1,222 differentially methylated regions in tissue samples (FDR<0.05) that were enriched in DNA replication-related pathways. Correlations between DNA methylation and clinical characteristics revealed significant differential methylation patterns between smokers and nonsmokers (FDR<0.05) in both tissue and plasma. Interpretation: Both tissue and ctDNA methylation can potentially be used as biomarkers for the early diagnosis of lung cancer. Funding: National Natural Science Foundation of China (81871890, 91859203). Declaration of Interest: The authors declare no potential conflicts of interest. Ethical Approval: The clinical protocol was approved by the Ethics Committee of West China Medical Center, and written informed consent was provided by all participants in this research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.